CME Group (NASDAQ:CME) Releases Earnings Results, Beats Estimates By $0.03 EPS

CME Group (NASDAQ:CME) posted its earnings results on Wednesday. The financial services provider reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.99 by $0.03, FiscalAI reports. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.71 billion. CME Group had a return on equity of 15.60% and a net margin of 63.30%.

CME Group Stock Performance

CME stock opened at $295.31 on Wednesday. The firm has a market cap of $106.19 billion, a PE ratio of 25.05, a P/E/G ratio of 3.79 and a beta of 0.24. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.13. The business has a 50 day moving average of $275.44 and a 200-day moving average of $270.55. CME Group has a 12-month low of $218.31 and a 12-month high of $329.16.

CME Group Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 25th. Stockholders of record on Wednesday, September 9th were issued a $1.30 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $5.20 annualized dividend and a dividend yield of 1.8%. CME Group’s dividend payout ratio is currently 44.11%.

Analysts Set New Price Targets

Several brokerages recently issued reports on CME. Bank of America upped their price target on CME Group from $226.00 to $230.00 and gave the stock an “underperform” rating in a report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft lowered CME Group from a “buy” rating to a “hold” rating and lowered their price target for the company from $286.00 to $270.00 in a research report on Wednesday, August 19th. Wells Fargo & Company raised their price objective on CME Group from $301.00 to $315.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Morgan Stanley raised their price objective on CME Group from $330.00 to $337.00 and gave the company an “overweight” rating in a research note on Friday, October 9th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $320.00 price objective on shares of CME Group in a report on Thursday, July 2nd. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $292.94.

Insider Activity at CME Group

In related news, Director Elizabeth Cook sold 500 shares of CME Group stock in a transaction on Monday, September 14th. The stock was sold at an average price of $280.11, for a total transaction of $140,055.00. Following the sale, the director directly owned 17,916 shares in the company, valued at approximately $5,018,450.76. This trade represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Terrence Duffy sold 15,000 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $274.44, for a total value of $4,116,600.00. Following the completion of the transaction, the chief executive officer directly owned 40,630 shares in the company, valued at approximately $11,150,497.20. This represents a 26.96% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.30% of the stock is currently owned by company insiders.

CME Group News Roundup

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Record revenue and earnings beat: Third-quarter revenue reached a record $1.74 billion, above the $1.71 billion consensus estimate, while adjusted EPS of $3.02 exceeded expectations of $2.99. Net income totaled $1.04 billion and operating income was $1.14 billion. CME Group Q3 earnings release
• Positive Sentiment: Trading volumes remained strong: Average daily volume rose to a third-quarter record of 29.4 million contracts, including 9 million contracts from outside the United States. Clearing and transaction-fee revenue reached $1.4 billion, supporting double-digit revenue and net-income growth. CME Q3 record revenue report
• Positive Sentiment: Market-data growth and capital returns: Market-data revenue increased 20% to a record $243 million. CME returned nearly $1 billion to shareholders through $465 million in dividends and $524 million in share repurchases, reinforcing its cash-generation profile.
• Positive Sentiment: Product expansion offers longer-term growth opportunities: CME is pursuing tungsten futures for the first half of 2027, pending regulatory approval, and has expanded its cryptocurrency derivatives offering with Bitcoin Cash and Uniswap futures. CME tungsten futures report
• Neutral Sentiment: Institutional positioning is mixed: JPMorgan and other investors added substantial CME shares, but several large firms, including T. Rowe Price, GQG Partners, FMR and Capital Research, reduced holdings.
• Negative Sentiment: Insider selling and regulatory uncertainty remain risks: Insiders made six sales versus three purchases over the past six months, including CEO Terrence Duffy’s sale of 50,000 shares. Separately, the CFTC is asking a court to dismiss CME’s lawsuit involving crypto perpetual futures, creating uncertainty around that initiative.

CME Group Company Profile

CME Group Inc operates global derivatives marketplaces that provide trading, clearing and settlement services for futures and options contracts. Its products cover major asset classes, including interest rates, equity indexes, foreign currencies, agricultural commodities, energy and metals. The company also provides market data, benchmark information and related services used by financial institutions, corporations, producers, investors and other market participants.

CME Group’s exchange portfolio includes CME, the Chicago Board of Trade, the New York Mercantile Exchange and COMEX.